• Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI study
• Phase 3 RESTORE registrational study enrolling participants, with site activation continuing in the United States and Canada

MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ:NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted NVG-291 Breakthrough Therapy designation for the treatment of chronic traumatic cervical motor-incomplete SCI. NVG-291 is being developed as potentially the first therapy to promote nerve regeneration in individuals living with chronic SCI.

Preliminary clinical evidence from the Phase 1b/2a CONNECT SCI study demonstrated substantial improvements on a clinically significant endpoint assessing functional hand use in individuals with chronic traumatic cervical motor-incomplete SCI. These findings were supported by Patient Global Impression of Change (PGIC) and blinded qualitative interviews documenting participant-reported gains in everyday function and independence compared to placebo. NVG-291 was generally well tolerated, with no serious adverse events or treatment discontinuations.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.